Evaxion Biotech A/S reports results for the quarter ended in January - Earnings Summary

Evaxion A/S

14/08/2024 14:52

* Evaxion Biotech A/S  EVAX.OQ  reported a quarterly
adjusted loss
of 12 cents​​ per share for the quarter ended in January, higher
than the same quarter last year, when the company reported EPS
of $-2.10.  The mean expectation of two analysts for the quarter
was for a loss of 39 cents per share. Wall Street expected
results to range from -70 cents to -8 cents per share.
    * Revenue was $154.00 thousand​; analysts expected $52.00
thousand. 
    * Evaxion Biotech A/S's reported EPS for the quarter was a
loss
of 12 cents​.
    * The company reported a quarterly loss of $6.2 million.
    * Evaxion Biotech A/S shares had fallen by 6.7% this
quarter and
lost 60.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 22% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Evaxion Biotech
A/S is $8.00 
This summary was machine generated from LSEG data August 14 at
01:51 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.39          -0.12          Beat
 Mar. 31 2024      -0.55          0.30           Beat
 Dec. 31 2023      -1.60          -1.60          Met
 Sep. 30 2023      -1.95          -2.10          Missed